

## Merodis advises Laboratoires Trenker on its sale to Erudite.Health

July 1<sup>st</sup>, 2024, Brussels, Belgium.

**Merodis** ([www.merodis.com](http://www.merodis.com)), an independent corporate finance advisory firm, is pleased to announce it has successfully advised the shareholders of Laboratoires Trenker on the sale to Belgian-based family company Erudite.Health. Laboratoires Trenker is a frontrunner in the Belux OTC pharma market through a proprietary branded portfolio of top-tier food supplements and medicines. Following the competitive auction process run by Merodis, Laboratoires Trenker has found with Erudite.Health a perfect fit regarding strategy, culture and ambitious market expansion which also ensures that Trenker's rich heritage as a 3<sup>rd</sup> generation family-owned company remains strongly anchored in Belgium. For Erudite.Health, Laboratoires Trenker ornaments the cornerstone of its pharmaceutical group, offering a platform for internationalization and accelerating its mission to transform personalized healthcare. The selling shareholders, Rodolphe and Pascale Trenker, will stay invested in the Company alongside its new owners.


**Laboratoires Trenker** ([www.trenker.be](http://www.trenker.be)) is a leading Belgian OTC/OTX pharmaceutical company. The company employs 90+ persons and currently generates EUR 28m in sales. Founded in 1933, Trenker has an extensive legacy as an innovative laboratory creating market-leading branded food supplement products such as Alline, Biocondil, Mobilityl, NC2 and Imutis. The company develops and manufactures most of its high-quality food supplements and medicines in its proprietary state-of-the-art production facility that complies with the strictest European production regulations for medicines (GMP) and food supplements (HACCP).

**Erudite.Health** (<https://erudite.health/>) is a Belgian-based family company, founded by Charles and Louis Declerck, aiming to redefine healthcare with comprehensive, evidence-based practices that prioritize patient involvement and well-being. Erudite.Health is divided into three pillars: Erudite.Healthtech, Erudite.Pharma, and Erudite.Therapeutics. This strategy integrates advanced OTC/OTX products, AI, and innovative pharmaceuticals. The company's team combines in-depth knowledge in the medical and pharmaceutical fields with scientific rigor and validation in its healthcare approach, ensuring patient-centric care from diagnosis through treatment and beyond.

### For more information, please contact:

Dirk Marckx, [dma@merodis.com](mailto:dma@merodis.com), +32 495 38 17 81

Fabian D'Hoore, [fdh@merodis.com](mailto:fdh@merodis.com), +32 497 38 29 01



## **About Merodis**

We provide middle-market companies and, or their shareholders with an ultra-focused, highly qualitative financial advisory service in support of trade sales (divestitures) or acquisitions and financing. For more information, recent transactions and credentials, please visit [www.merodis.com](http://www.merodis.com). If you no longer wish to receive this information, please send an email with subject "Unsubscribe" to [info@merodis.com](mailto:info@merodis.com).

If you want to get the latest news about Merodis, please click <https://merodis.com/contact/>